151 related articles for article (PubMed ID: 8569225)
1. Ketanserin lowers erythropoietin concentration in hemodialyzed patients treated with the hormone.
Borawski J; Mazerska M; Pawlak K; Mysliwiec M
J Cardiovasc Pharmacol; 1995 Oct; 26(4):621-6. PubMed ID: 8569225
[TBL] [Abstract][Full Text] [Related]
2. [Ketanserin decreases erythropoietin concentration in hemodialyzed patients on rHuEPO therapy].
Borawski J; Mazerska M; Pawlak K; Myśliwiec M
Pol Arch Med Wewn; 1994; 92 Spec No():14-20. PubMed ID: 7731894
[TBL] [Abstract][Full Text] [Related]
3. A study of platelet functions, some hemostatic and fibrinolytic parameters in relation to serotonin in hemodialyzed patients under erythropoietin therapy.
Malyszko J; Malyszko JS; Borawski J; Rydzewski A; Kalinowski M; Azzadin A; Mysliwiec M; Buczko W
Thromb Res; 1995 Jan; 77(2):133-43. PubMed ID: 7740505
[TBL] [Abstract][Full Text] [Related]
4. Long-term effects of erythropoietin on platelet serotonin storage and platelet aggregation in hemodialysis patients with reference to ketanserin treatment.
Borawski J; Rydzewski A; Pawlak K; Azzadin A; Buczko W; Mysliwiec M
Thromb Res; 1998 May; 90(4):171-80. PubMed ID: 9692616
[TBL] [Abstract][Full Text] [Related]
5. [Influence of long-term erythropoietin (rHuEPO) therapy on the function of the pituitary-gonadal axis in hemodialyzed male patients with end stage renal failure].
Trembecki J; Kokot F; Wiecek A; Marcinkowski W; Rudka R
Pol Arch Med Wewn; 1995 Aug; 94(2):144-52. PubMed ID: 8596749
[TBL] [Abstract][Full Text] [Related]
6. Inverse relationships between haemoglobin and ristocetin-induced platelet aggregation in haemodialysis patients under erythropoietin therapy.
Borawski J; Rydzewski A; Mazerska M; Kalinowski M; Pawlak K; Mysliwiec M
Nephrol Dial Transplant; 1996 Dec; 11(12):2444-8. PubMed ID: 9017620
[TBL] [Abstract][Full Text] [Related]
7. Effect of subcutaneous and intraperitoneal administration of recombinant human erythropoietin on blood pressure and vasoactive hormones in patients on continuous ambulatory peritoneal dialysis.
Lai KN; Lui SF; Leung JC; Law E; Nicholls MG
Nephron; 1991; 57(4):394-400. PubMed ID: 1828543
[TBL] [Abstract][Full Text] [Related]
8. Leptin and serum erythropoietin in hemodialyzed and peritoneally dialyzed uremic patients during rHuEPO therapy.
Małyszko J; Zbroch E; Wołczyński S; Małyszko JS; Hryszko T; Myśliwiec M
Am J Nephrol; 2000; 20(3):180-6. PubMed ID: 10878398
[TBL] [Abstract][Full Text] [Related]
9. Comparison of plasma erythropoietin concentrations and iron status in hemodialyzed patients not requiring and requiring rHuEpo therapy.
Majdan M; Ksiazek A; Kozioł M; Spasiewicz D; Swatowski A; Solski J
Nephron; 1996; 73(3):425-9. PubMed ID: 8832602
[TBL] [Abstract][Full Text] [Related]
10. Serum soluble transferrin receptor reflects erythropoiesis but not iron availability in erythropoietin-treated chronic hemodialysis patients.
Chiang WC; Tsai TJ; Chen YM; Lin SL; Hsieh BS
Clin Nephrol; 2002 Nov; 58(5):363-9. PubMed ID: 12425487
[TBL] [Abstract][Full Text] [Related]
11. Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients.
Carlini R; Obialo CI; Rothstein M
Am J Hypertens; 1993 Feb; 6(2):103-7. PubMed ID: 8471228
[TBL] [Abstract][Full Text] [Related]
12. Quantitative reticulocyte analysis may be of benefit in monitoring erythropoietin treatment in dialysis patients.
Jeffrey RF; Khan AA; Kendall RG; Norfolk DR; Will EJ; Davison AM
Artif Organs; 1995 Aug; 19(8):821-6. PubMed ID: 8573002
[TBL] [Abstract][Full Text] [Related]
13. Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin.
Watson AJ; Gimenez LF; Cotton S; Walser M; Spivak JL
Am J Med; 1990 Oct; 89(4):432-5. PubMed ID: 2220877
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of platelet function during treatment with recombinant human erythropoietin (r-HuEPO) in patients hemodialyzed and dialyzed peritoneally].
Janicka L; Majdan M; Dmoszyńska A; Ksiazek A; Berger B; Baranowska E
Wiad Lek; 1993 Oct; 46(19-20):756-60. PubMed ID: 7975620
[TBL] [Abstract][Full Text] [Related]
15. Anemia and carnitine supplementation in hemodialyzed patients.
Kletzmayr J; Mayer G; Legenstein E; Heinz-Peer G; Leitha T; Hörl WH; Kovarik J
Kidney Int Suppl; 1999 Mar; 69():S93-106. PubMed ID: 10084293
[TBL] [Abstract][Full Text] [Related]
16. Effect of low dose recombinant human omega erythropoietin (rHuEPO) on anaemia in patients on hemodialysis.
Acharya VN; Sinha DK; Almeida AF; Pathare AV
J Assoc Physicians India; 1995 Aug; 43(8):539-42. PubMed ID: 8772973
[TBL] [Abstract][Full Text] [Related]
17. Ketanserin: a new perspective in posttransplant erythrocytosis?
Borawski J; Mazerska M; Rydzewski A; Pawlak K; Rowinski M; Mysliwiec M
Clin Transplant; 1996 Feb; 10(1 Pt 1):63-6. PubMed ID: 8652901
[TBL] [Abstract][Full Text] [Related]
18. Influence of acetate and bicarbonate hemodialysis on the plasma erythropoietin concentration in patients with chronic renal failure.
Wiecek A; Franek E; Kokot F; Rudka R
Int J Artif Organs; 1997 Feb; 20(2):108-11. PubMed ID: 9093890
[TBL] [Abstract][Full Text] [Related]
19. Is erythropoietin a survival factor for red blood cells?
Polenakovic M; Sikole A
J Am Soc Nephrol; 1996 Aug; 7(8):1178-82. PubMed ID: 8866410
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of platelet hyperfunction in hemodialysis patients receiving recombinant human erythropoietin.
Zirkman DM; Zeigler ZR; Fraley DS; Bruns FJ; Adler S
Am J Kidney Dis; 1993 Jan; 21(1):31-7. PubMed ID: 8418623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
